Unknown

Dataset Information

Characterization of β-Lactamase Content of Ceftazidime-Resistant Pathogens Recovered during the Pathogen-Directed Phase 3 REPRISE Trial for Ceftazidime-Avibactam: Correlation of Efficacy against β-Lactamase Producers.


ABSTRACT: REPRISE was a pathogen-directed (ceftazidime-resistant) phase 3 prospective, open-label, randomized, multicenter trial that evaluated the efficacy, safety, and tolerability of ceftazidime-avibactam (CAZ-AVI) and best available therapy (BAT) in the treatment of hospitalized adults with complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI). This study characterized the β-lactamase content of ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa recovered during the baseline visits of patients enrolled in REPRISE. Ceftazidime had MIC90 results of >64 μg/ml against baseline Enterobacteriaceae and P. aeruginosablaCTX-M variants were the most common β-lactamases found in Escherichia coli (detected in 94.3% of all E. coli isolates) and Klebsie

SUBMITTER: Mendes RE 

PROVIDER: S-EPMC6535560 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature